Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase
Posted by rob on June 15, 2011 under Uncategorized | 
Comments are off for this article
Abstract Chronic myelogenous leukemia, BCR-ABL1+ (CML) is a myeloproliferative neoplasm defined by the presence of the BCR-ABL fusion gene and a t(9;22)(q34;q11) cytogenetic abnormality. Its natural history is that of inexorable progression to an acute
leukemia (blast crisis) after a prolonged chronic phase. The recent development of imatinib and other inhibitors of BCR-ABL tyrosine kinase activity has dramatically altered the clinical course of CML, with long-term remissions in most patients
treated early in the course of the disease. Monitoring of resistance to therapy and progression on therapy are critical in
the current management of the disease. Problems facing the diagnostic pathologist in this “Age of Imatinib” include accurate
diagnosis and determination of CML …
MedWorm Message: Find out how you can get your message posted here and on over 100,000 other medical web pages in just a couple of days, plus support MedWorm at the same time.